

Mohammed s Alesawy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2013220/publications.pdf>

Version: 2024-02-01

15
papers

518
citations

840776

11
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

216
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 573-591.	5.2	23
2	Design, synthesis, in silico ADMET, docking, and antiproliferative evaluations of [1,2,4]triazolo[4,3-c]quinazolines as classical DNA intercalators. <i>Archiv Der Pharmazie</i> , 2022, , e2100412.	4.1	8
3	Antiproliferative evaluations of triazoloquinazolines as classical DNA intercalators: Design, synthesis, ADMET profile, and molecular docking. <i>Archiv Der Pharmazie</i> , 2022, 355, e2100487.	4.1	5
4	Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2'-O-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs. <i>Molecules</i> , 2022, 27, 2287.	3.8	34
5	Triazoloquinazoline derived classical DNA intercalators: Design, synthesis, in silico ADME profile, docking, and antiproliferative evaluations. <i>Archiv Der Pharmazie</i> , 2022, 355, e2100506.	4.1	7
6	Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2. <i>Bioorganic Chemistry</i> , 2022, 123, 105770.	4.1	48
7	Ligand-based design and synthesis of <i>N'</i> -Benzylidene-3,4-dimethoxybenzohydrazide derivatives as potential antimicrobial agents; evaluation by <i>in vitro</i> , <i>in vivo</i> , and <i>in silico</i> approaches with SAR studies. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1098-1119.	5.2	27
8	Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: <i>in vitro</i> anticancer evaluation and <i>in silico</i> studies. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1903-1917.	5.2	64
9	New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation. <i>Archiv Der Pharmazie</i> , 2022, 355, .	4.1	6
10	Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors. <i>Archiv Der Pharmazie</i> , 2021, 354, e2000237.	4.1	51
11	[1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 30, 115958.	3.0	46
12	In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (Mpro). <i>Molecules</i> , 2021, 26, 2806.	3.8	46
13	Design and synthesis of new 4-(2-nitrophenoxy)benzamide derivatives as potential antiviral agents: molecular modeling and <i>in vitro</i> antiviral screening. <i>New Journal of Chemistry</i> , 2021, 45, 16557-16571.	2.8	46
14	In Silico Screening of Semi-Synthesized Compounds as Potential Inhibitors for SARS-CoV-2 Papain-like Protease: Pharmacophoric Features, Molecular Docking, ADMET, Toxicity and DFT Studies. <i>Molecules</i> , 2021, 26, 6593.	3.8	35
15	Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPAR β and SUR agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 4723-4744.	3.0	72